Regarding safety outcomes, both highly selective and non-selective SGLT2 inhibitors increased the risk of genital infections and diabetic ketoacidosis to a similar extent in patients with type 2 diabetes, as compared with placebo. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.